Männedorf, Switzerland, October 3, 2016 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has successfully completed the acquisition of SPEware Corporation (SPEware) on September 30, 2016. On August 31, 2016, Tecan announced the acquisition of SPEware, a leading provider for mass spectrometry sample preparation solutions based in Baldwin Park, California (USA), to further expand Tecan's dedicated solutions offering into a new market segment. From October 1, 2016, SPEware will be included in the consolidated financial statements of the Tecan Group as a part of the Life Sciences Business segment.
Additional information can be found on the SPEware webpage:
Tecan ( www.tecan.com ) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2015, Tecan generated sales of CHF 440 million (USD 459 million; EUR 411 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:Press Release
Last updated on: 04/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.